Reach Us +1-217-403-9671
Overview Of Submission Of Summary Bioequivalence Data For ANDAs | 8249
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Overview of submission of summary Bioequivalence data for ANDAs

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Ethan Stier

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

T he Food and Drug Administration (FDA) amended its regulations on the submission of bioequivalence data to require an abbreviated new drug application (ANDA) applicant to submit data from all bioequivalence (BE) studies the applicant conducts on a drug product formulation submitted for approval. In the past, ANDA applicants submitted BE studies demonstrating that a generic product meets bioequivalence criteria in order for FDA to approve the ANDA, but have not typically submitted additional BE studies conducted on the same drug product formulation, such as studies that do not show that the product meets these criteria. In some cases, fi rms may conduct pilot studies on formulations other than the same drug product formulation. Th e presentation will focus on how to determine if a formulation is considered to be a ?same drug product formulation? and, if so, how to submit the study in the ANDA
Ethan M. Stier, R.Ph., Ph.D., is currently acting Deputy Director in the Division of Bioequivalence II in the Of fi ce of Generic Drugs, CDER, FDA. Dr. Stier earned his Ph.D. in Pharmaceutics from the University of Michigan and pharmacy degree from the University of Connecticut. His graduate work focused on protein delivery using liposomal delivery. His current research interests focus on the use of computer simulation to predict bioequivalence and on establishing bioequivalence approaches for complex dosage forms